The application of corticosteroids for pathological scar prevention and treatment: current review and update

Abstract

The prevention and treatment of pathological scars remain challenging. Corticosteroids are the mainstay drugs in clinical scar prevention and treatment as they effectively induce scar regression and improve scar pruritus and pain. Currently, intralesional injections of corticosteroids are widely used in clinical practice. These require professional medical manipulation; however, the significant accompanying injection pain, repetition of injections and adverse effects, such as skin atrophy, skin pigmentation and telangiectasia, make this treatment modality an unpleasant experience for patients. Transdermal administration is, therefore, a promising non-invasive and easy-to-use method for corticosteroid administration for scar treatment. In this review, we first summarize the mechanisms of action of corticosteroids in scar prevention and treatment; then, we discuss current developments in intralesional injections and the progress of transdermal delivery systems of corticosteroids, as well as their corresponding advantages and disadvantages.

Keywords

Corticosteroids / Pathological scar / Prevention and treatment / Transdermal drug delivery / Administration method

References

[1] Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci. 2018; 19: 711.

[2] Trace AP, Enos CW, Mantel A, Harvey VM. Keloids and hypertrophic scars: a spectrum of clinical challenges. Am J Clin Dermatol. 2016; 17: 201-23.

[3] Shirakami E, Yamakawa S, Hayashida K. Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence. Burns Trauma. 2020; 8: tkz003.

[4] Lv K, Xia Z, On behalf of the Chinese consensus panel on the prevention and treatment of scars. Chinese expert consensus on clinical prevention and treatment of scar. Burns Trauma. 2018; 6: 6.

[5] Ogawa R, Akita S, Akaishi S, Aramaki-Hattori N, Dohi T, Hayashi T, et al. Diagnosis and treatment of keloids and hypertrophic scars-Japan scar workshop consensus document 2018. Burns Trauma. 2019; 7: 39.

[6] Abedini R, Sasani P, Mahmoudi HR, Nasimi M, Teymournpour A, Shadlou Z. Comparison of intralesional verapamil versus intralesional corticosteroids in treatment of keloids and hypertrophic scars: a randomized controlled trial. Burns. 2018; 44: 1482-8.

[7] Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids: a 2020 update of the algorithms published 10 years ago. Plast Reconstr Surg. 2022; 149: 79.

[8] Trisliana, Perdanasari A, Torresetti M, Grassetti L, Nicoli F, Zhang YX, Dashti T, et al. Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes. Burns Trauma. 2015; 3: 14.

[9] Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017; 18: 606.

[10] Qian LW, Fourcaudot AB, Yamane K, You T, Chan RK, Leung KP. Exacerbated and prolonged inflammation impairs wound healing and increases scarring. Wound Repair Regen. 2016; 24: 26-34.

[11] Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005; 353: 1711-23.

[12] Wang L, Yang M, Wang X, Cheng B, Ju Q, Eichenfield D, et al. Glucocorticoids promote CCL20 expression in keratinocytes. Br J Dermatol. 2021; 185: 1200-8.

[13] Ayroldi E, Cannarile L, Migliorati G, Nocentini G, Delfino DV, Riccardi C. Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways. FASEB J. 2012; 26: 4805-20.

[14] Ingawale DK, Mandlik SK. New insights into the novel anti-inflammatory mode of action of glucocorticoids. Immunopharmacol Immunotoxicol. 2020; 42: 59-73.

[15] Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol. 2002; 3: 47-58.

[16] De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev. 2003; 24: 488-522.

[17] Kan M, Himes BE. Insights into glucocorticoid responses derived from omics studies. Pharmacol Ther. 2021; 218: 107674.

[18] Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-all-Rounders tackling the versatile players of the immune system. Front Immunol. 2019; 10: 1744.

[19] Shimba A, Ikuta K (eds). Control of immunity by glucocorticoids in health and disease. Semin Immunopathol, Berlin Heidelberg: Springer, 2020; Vol. 42, pp. 669-680.

[20] Wu W-S, Wang F-S, Yang KD, Huang C-C, Kuo Y-R. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. J Invest Dermatol. 2006; 126: 1264-71.

[21] Bao W, Xu S. Mechanism of abnormal scars with treatment of steroid. Zhonghua Wai Ke Za Zhi. 2000; 38: 378-81.

[22] Yuan B, Upton Z, Leavesley D, Fan C, Wang X-Q. Vascular and collagen target: a rational approach to hypertrophic scar management. Adv Wound Care (New Rochelle). 2023; 12: 38-55.

[23] Carroll LA, Hanasono MM, Mikulec AA, Kita M, Koch RJ. Triamcinolone stimulates bFGF production and inhibits TGF-β1 production by human dermal fibroblasts. Dermatol Surg. 2002; 28: 704-9.

[24] Tan E, Rouda S, Greenbaum S, Moore J, Jr, Fox J, Sollberg S. Acidic and basic fibroblast growth factors down-regulate collagen gene expression in keloid fibroblasts. Am J Pathol. 1993; 142: 463.

[25] Raghow R, Postlethwaite A, Keski-Oja J, Moses H, Kang AH. Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest. 1987; 79: 1285-8.

[26] Roques C, Téot L. The use of corticosteroids to treat keloids: a review. Int J Low Extrem Wounds. 2008; 7: 137-45.

[27] Diegelmann RF, Bryant CP, Cohen IK. Tissue alpha-globulins in keloid formation. Plast Reconstr Surg. 1977; 59: 418-23.

[28] Wang F, Yang H, Liao H, Li W, Liu W. Treatment of auricular keloids with surgery and intralesional injection of compound betamethasone. Zhonghua Zheng Xing wai ke za zhi. 2014; 30: 7-10.

[29] McKenzie A, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol. 1962; 86: 608-10.

[30] Sysa-Jędrzejowska A. Topical steroids-a new approach after 50 years. Med Sci Monit. 2001; 7: RA539-44.

[31] Haigh JM, Kanfer I. Assessment of topical corticoeroid preparations: the human skin blanching assay. Int J Pharm. 1984; 19: 245-62.

[32] Görne R, Greif C, Metzner U, Wigger-Alberti W, Elsner P. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers. Skin Pharmacol Physiol. 2007; 20: 133-40.

[33] Pershing LK. Assessment of topical corticosteroid-induced skin blanching response using the visual McKenzie-Stoughton and colorimetric methods. Drug Inf J. 1995; 29: 923-34.

[34] Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009; 79: 135-40.

[35] Stacey SK, McEleney M. Topical corticosteroids: choice and application. Am Fam Physician. 2021; 103: 337-43.

[36] Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019; 46: 1053-101.

[37] Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm. 2008; 68: 453-66.

[38] Sun P, Lu X, Zhang H, Hu Z. The efficacy of drug injection in the treatment of pathological scar: a network meta-analysis. Aesthet Plast Surg. 2021; 45: 791-805.

[39] Davison SP, Dayan JH, Clemens MW, Sonni S, Wang A, Crane A. Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids. Aesthet Plast Surg. 2009; 29: 40-6.

[40] Saki N, Mokhtari R, Nozari F. Comparing the efficacy of intralesional triamcinolone acetonide with verapamil in treatment of keloids: a randomized controlled trial. Dermatol Pract Concept. 2019; 9: 4.

[41] Nedelec B, LaSalle L, de Oliveira A, Correa JA. Within-patient, single-blinded, randomized controlled clinical trial to evaluate the efficacy of triamcinolone Acetonide injections for the treatment of hypertrophic scar in adult burn survivors. J Burn Care Res. 2020; 41: 761-9.

[42] Wang P, Gu L, Bi H, Wang Q, Qin Z. Comparing the efficacy and safety of intralesional verapamil with intralesional triamcinolone acetonide in treatment of hypertrophic scars and keloids: a meta-analysis of randomized controlled trials. Aesthet Surg J. 2021; 41: NP567-75.

[43] Wong T-S, Li JZ-H, Chen S, Chan JY-W, Gao W. The efficacy of triamcinolone acetonide in keloid treatment: a systematic review and meta-analysis. Front Med (Lausanne). 2016; 3: 71.

[44] Gold MH, McGuire M, Mustoe TA, Pusic A, Sachdev M, Waibel J, et al. Updated international clinical recommendations on scar management: part 2-algorithms for scar prevention and treatment. Dermatol Surg. 2014; 40: 825-31.

[45] Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999; 104: 1435-58.

[46] Park TH, Seo SW, Kim J-K, Chang CH. Clinical characteristics of facial keloids treated with surgical excision followed by intra-and postoperative intralesional steroid injections. Aesthet Plast Surg. 2012; 36: 169-73.

[47] Hung Y-T, Lin S-M, Tzeng I, Ng CY. Optimizing surgical outcome of auricular keloid with a novel multimodal approach. Sci Rep. 2022; 12: 1-8.

[48] Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004; 3: 115-24.

[49] Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008; 26: 1261-8.

[50] Yii N, Frame J. Evaluation of cynthaskin and topical steroid in the treatment of hypertrophic scars and keloids. Eur J Plast Surg. 1996; 19: 162-5.

[51] Hayashi T, Furukawa H, Oyama A, Funayama E, Saito A, Murao N, et al. A new uniform protocol of combined corticosteroid injections and ointment application reduces recurrence rates after surgical keloid/hypertrophic scar excision. Dermatol Surg. 2012; 38: 893-7.

[52] Goldman L, Igelman J, Kitzmiller K. Clinical investigative studies with flurandrenolone tape. Cutis. 1967; 3: 367-71.

[53] Ogawa R, Akaishi S. Effectiveness of corticosteroid tape/plasters for keloids and hypertrophic scars-comparative study of fludroxycortide and deprodone propionate tape/plasters. Scar Manag. 2016; 10: 55-60.

[54] Ly S, Amici JM. Role of betamethasone valerate 2.250 mg medicated plaster in the treatment of psoriasis and other dermatological pathologies: a review. Drugs. Context. 2018; 7: 212539.

[55] Bonavita M, Soresina M, Boccanera D, Bianchi F. Efficacy and tolerability of a new pharmaceutical form of betamethasone Valerate in the prevention of hypertrophic scars following anterior trunk plastic surgery: a preliminary exploratory study. Eur J Inflamm. 2014; 12: 459-65.

[56] Goutos I, Ogawa R. Steroid tape: a promising adjunct to scar management. Scars Burn Heal. 2017; 3: 2059513117690937.

[57] Phatale V, Vaiphei KK, Jha S, Patil D, Agrawal M, Alexander A. Overcoming skin barriers through advanced transdermal drug delivery approaches. J Control Release. 2022; 351: 361-80.

[58] Al-Japairai KAS, Mahmood S, Almurisi SH, Venugopal JR, Hilles AR, Azmana M, et al. Current trends in polymer microneedle for transdermal drug delivery. Int J Pharm. 2020; 587: 119673.

[59] Tan CW, Tan WD, Srivastava R, Yow AP, Wong DW, Tey HL. Dissolving triamcinolone-embedded microneedles for the treatment of keloids: a single-blinded intra-individual controlled clinical trial. Dermatol Ther (Heidelb). 2019; 9: 601-11.

[60] Lin S, Quan G, Hou A, Yang P, Peng T, Gu Y, et al. Strategy for hypertrophic scar therapy: improved delivery of triamcinolone acetonide using mechanically robust tip-concentrated dissolving microneedle array. J Control Release. 2019; 306: 69-82.

[61] Yang B, Dong Y, Shen Y, Hou A, Quan G, Pan X, et al. Bilayer dissolving microneedle array containing 5-fluorouracil and triamcinolone with biphasic release profile for hypertrophic scar therapy. Bioact Mater. 2021; 6: 2400-11.

[62] Li M, Vora LK, Peng K, Donnelly RF. Trilayer microneedle array assisted transdermal and intradermal delivery of dexamethasone. Int J Pharm. 2022; 612: 121295.

[63] Yu Z, Meng X, Zhang S, Chen Y, Zhang Z, Zhang Y. Recent progress in transdermal Nanocarriers and their surface modifications. Molecules. 2021; 26: 3093.

[64] Raposo SC, Simoes SD, Almeida AJ, Ribeiro HM. Advanced systems for glucocorticoids’ dermal delivery. Expert Opin Drug Deliv. 2013; 10: 857-77.

[65] Sguizzato M, Esposito E, Cortesi R. Lipid-based nanosystems as a tool to overcome skin barrier. Int J Mol Sci. 2021; 22: 8319.

[66] Qu F, Geng R, Liu Y, Zhu J. Advanced nanocarrier-and microneedle-based transdermal drug delivery strategies for skin diseases treatment. Theranostics. 2022; 12: 3372.

[67] Shetty K, Sherje AP. Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis-a systematic review. J Mater Sci Mater Med. 2021; 32: 1-29.

[68] Madan JR, Khude PA, Dua K. Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. Int J Pharm Investig. 2014; 4: 60.

[69] Fesq H, Lehmann J, Kontny A, Erdmann I, Theiling K, Rother M, et al. Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome^® in comparison with equipotent cream and ointment: a randomized controlled trial. Br J Dermatol. 2003; 149: 611-9.

[70] Amiri M, Khazaeli P, Salehabadi A, Salavati-Niasari M. Hydrogel beads-based nanocomposites in novel drug delivery platforms: recent trends and developments. Adv Colloid Interf Sci. 2021; 288: 102316.

[71] Koh E, Freedman BR, Ramazani F, Gross J, Graham A, Kuttler A, et al. Controlled delivery of corticosteroids using Tunable tough adhesives. Adv Healthc Mater. 2022; 12: 2201000.

[72] Braun SA, Schrumpf H, Buhren BA, Homey B, Gerber PA. Laser-assisted drug delivery: mode of action and use in daily clinical practice. J Dtsch Dermatol Ges. 2016; 14: 480-8.

[73] Lin C-H, Aljuffali IA, Fang J-Y. Lasers as an approach for promoting drug delivery via skin. Expert Opin Drug Deliv. 2014; 11: 599-614.

[74] Singhal M, del Río-Sancho S, Sonaje K, Kalia YN. Fractional laser ablation for the cutaneous delivery of triamcinolone acetonide from cryomilled polymeric microparticles: creating intraepidermal drug depots. Mol Pharm. 2016; 13: 500-11.

[75] Tawaranurak N, Pliensiri P, Tawaranurak K. Combination of fractional carbon dioxide laser and topical triamcinolone vs intralesional triamcinolone for keloid treatment: a randomised clinical trial. Int Wound J. 2022; 19: 1729-35.

[76] Park JH, Chun JY, Lee JH. Laser-assisted topical corticosteroid delivery for the treatment of keloids. Lasers Med Sci. 2017; 32: 601-8.

[77] Azagury A, Khoury L, Enden G, Kost J. Ultrasound mediated transdermal drug delivery. Adv Drug Deliv Rev. 2014; 72: 127-43.

[78] Maruani A, Boucaud A, Perrodeau E, Gendre D, Giraudeau B, Machet L. Low-frequency ultrasound sonophoresis to increase the efficiency of topical steroids: a pilot randomized study of humans. Int J Pharm. 2010; 395: 84-90.

[79] Issa MC, Kassuga LE, Chevrand NS, Pires MT. Topical delivery of triamcinolone via skin pretreated with ablative radiofrequency: a new method in hypertrophic scar treatment. Int J Dermatol. 2013; 52: 367-70.

[80] Schramm-Baxter J, Mitragotri S. Needle-free jet injections: dependence of jet penetration and dispersion in the skin on jet power. J Control Release. 2004; 97: 527-35.

[81] Barolet D, Benohanian A. Current trends in needle-free jet injection: an update. Clin Cosmet Investig Dermatol. 2018; 11: 231.

[82] Levenberg A, Vinshtok Y, Artzi O. Potentials for implementing pressure-controlled jet injection in management of keloids with intralesional 5FU and corticosteroids. J Cosmet Dermatol. 2020; 19: 1966-72.

[83] Priya B, Rashmi T, Bozena M. Transdermal iontophoresis. Expert Opin Drug Deliv. 2006; 3: 127-38.

[84] Wang Y, Zeng L, Song W, Liu J. Influencing factors and drug application of iontophoresis in transdermal drug delivery: an overview of recent progress. Drug Deliv. Transl Res. 2022; 12: 15-26.

[85] Kováčik A, Kopečná M, Vávrová K. Permeation enhancers in transdermal drug delivery: benefits and limitations. Expert opinion on drug delivery. 2020; 17: 145-55.

[86] Carvajal-Vidal P, Mallandrich M, García ML, Calpena AC. Effect of different skin penetration promoters in halobetasol propionate permeation and retention in human skin. Int J Mol Sci. 2017; 18: 2475.

[87] Dolz-Pérez I, Sallam MA, Masiá E, Morelló-Bolumar D, Del Caz MDP, Graff P, et al. Polypeptide-corticosteroid conjugates as a topical treatment approach to psoriasis. J Control Release. 2020; 318: 210-22.